Several compounds were targeting the PI3K/AKT pathway, such as rigosertib, MK-2206, AZD6482, TGX-221, NVP-BEZ235, and targeting the JAK/STAT pathway, like ruxolitinib and AZD1480, which were significantly correlated to STAT3 expression in cancer cell lines. This evidence concerns the gene AKT1 and cancer.